NK Cell Therapy
The immune system, quietly rehearsed.
Overview
An autologous immune cell therapy that expands your own natural killer cells to therapeutic quantities, restoring the body's principal line of defence against malignant and virally-infected cells.
A protocol developed with Prof. Masuyama in Japan: natural killer cells are drawn, expanded ex-vivo, and reintroduced to reinforce the body's own surveillance systems.
The intent is resilience — a strengthened first line against cellular disorder, delivered without theatre in a private suite.
The Science
Why this works.
- 01
Natural killer (NK) cells are innate lymphocytes that detect and eliminate cellular abnormalities without prior sensitisation — the immune system's earliest surveillance layer.
- 02
NK activity declines measurably with age; by the sixth decade, cytotoxicity is often less than half of youthful function.
- 03
The Masuyama protocol expands NK cells ex-vivo by a factor of 1,000 to 10,000, restoring youthful cytotoxic capacity when reinfused.
The Process
A protocol conducted without theatre.
01
NK function panel
A baseline assay quantifies NK cell count and cytotoxic activity to establish candidacy.
02
Peripheral blood draw
A single 50 ml draw provides the starting cell population.
03
Ex-vivo expansion
Cells are cultured for approximately two weeks in a licensed Japanese laboratory under the Masuyama protocol.
04
Reinfusion
The expanded population is reinfused intravenously over ninety minutes in a private suite.
05
Follow-up assay
Cytotoxicity is re-measured at six and twelve weeks post-infusion.
Considered for
Members with documented low NK function on baseline diagnostics.
Those with a family history of malignancy pursuing preventative resilience.
Members recovering from viral illness or seeking systemic immune restoration.
Outcomes
- →
Measurable restoration of NK cytotoxic activity on repeat assay.
- →
Reinforced immune surveillance against transformed and virally-infected cells.
- →
Recommended cadence of two to four cycles per year for sustained effect.
Delivered under the clinical governance of Prof. Masuyama's Japanese laboratory, with all cell processing conducted to Japanese regulatory standards.